Ken Kato, MD, PhD, National Cancer Center Hospital East

Articles by Ken Kato, MD, PhD, National Cancer Center Hospital East

Applying Data to the Real World in Gastric Cancer

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Emerging Approaches in HER2+ Gastric Cancers

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

VEGFR TKIs in Gastroesophageal Cancer

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Maintenance Therapy in Gastric Cancers

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Adjuvant Treatment in Gastroesophageal Cancer

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Looking Toward the Future in Gastroesophageal Cancer

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Toxicity Management in Second Line for Gastric Cancer

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Clinical Rationale for Antiangiogenics in Gastric Cancer

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Predicting Response With Biomarkers in Gastric Cancers

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Applying New Data in the Real-World for GEJ Cancer

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

ESMO 2020: Practice-Changing Data in Esophageal Cancer

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

First-Line I/O Successful in Gastric Adenocarcinoma

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Treatment Landscape in Gastric Cancers Pre-ESMO 2020

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Frontline Treatment in Metastatic Gastric Cancer

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Optimal Approach Toward Advanced Gastric Cancers in US

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Global Trends in Gastric Cancers

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Latest Updated Articles

ESMO 2020: Practice-Changing Data in Esophageal Cancer
October 22nd 2020
First-Line I/O Successful in Gastric Adenocarcinoma
October 22nd 2020
Predicting Response With Biomarkers in Gastric Cancers
October 22nd 2020
Optimal Approach Toward Advanced Gastric Cancers in US
October 22nd 2020
Treatment Landscape in Gastric Cancers Pre-ESMO 2020
October 22nd 2020
Applying New Data in the Real-World for GEJ Cancer
October 22nd 2020

Ken Kato, MD, PhD, National Cancer Center Hospital East

Articles by Ken Kato, MD, PhD, National Cancer Center Hospital East

Applying Data to the Real World in Gastric Cancer

Emerging Approaches in HER2+ Gastric Cancers

VEGFR TKIs in Gastroesophageal Cancer

Maintenance Therapy in Gastric Cancers

Adjuvant Treatment in Gastroesophageal Cancer

Looking Toward the Future in Gastroesophageal Cancer

Toxicity Management in Second Line for Gastric Cancer

Clinical Rationale for Antiangiogenics in Gastric Cancer

Predicting Response With Biomarkers in Gastric Cancers

Applying New Data in the Real-World for GEJ Cancer

ESMO 2020: Practice-Changing Data in Esophageal Cancer

First-Line I/O Successful in Gastric Adenocarcinoma

Treatment Landscape in Gastric Cancers Pre-ESMO 2020

Frontline Treatment in Metastatic Gastric Cancer

Optimal Approach Toward Advanced Gastric Cancers in US

Global Trends in Gastric Cancers

Latest Updated Articles

Trending on OncLive

Epcoritamab Significantly Improves PFS Vs Chemoimmunotherapy in R/R Large B-Cell Lymphoma

MONUMENTAL-3 Data Support Talquetamab Plus Daratumumab ± Pomalidomide as a New SOC in R/R Myeloma

Luspatercept Misses Primary RBC-TI End Point But Shows Clinically Meaningful Improvement for Anemia in Myelofibrosis

FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC

CLL14 Final Analysis Shows Long-Term PFS Gain With Venetoclax/Obinutuzumab in Previously Untreated CLL